INmune Bio (INMB) Competitors $4.56 -0.15 (-3.18%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INMB vs. CDTX, XFOR, FBIO, AGTC, MBIO, VERV, LRMR, CGC, FDMT, and AKBAShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Cidara Therapeutics (CDTX), X4 Pharmaceuticals (XFOR), Fortress Biotech (FBIO), Applied Genetic Technologies (AGTC), Mustang Bio (MBIO), Verve Therapeutics (VERV), Larimar Therapeutics (LRMR), Canopy Growth (CGC), 4D Molecular Therapeutics (FDMT), and Akebia Therapeutics (AKBA). These companies are all part of the "medical" sector. INmune Bio vs. Cidara Therapeutics X4 Pharmaceuticals Fortress Biotech Applied Genetic Technologies Mustang Bio Verve Therapeutics Larimar Therapeutics Canopy Growth 4D Molecular Therapeutics Akebia Therapeutics INmune Bio (NASDAQ:INMB) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk. Does the MarketBeat Community prefer INMB or CDTX? Cidara Therapeutics received 307 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.09% of users gave INmune Bio an outperform vote while only 70.17% of users gave Cidara Therapeutics an outperform vote. CompanyUnderperformOutperformINmune BioOutperform Votes14076.09% Underperform Votes4423.91% Cidara TherapeuticsOutperform Votes44770.17% Underperform Votes19029.83% Does the media refer more to INMB or CDTX? In the previous week, Cidara Therapeutics had 4 more articles in the media than INmune Bio. MarketBeat recorded 8 mentions for Cidara Therapeutics and 4 mentions for INmune Bio. Cidara Therapeutics' average media sentiment score of 0.53 beat INmune Bio's score of 0.22 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is INMB or CDTX more profitable? Cidara Therapeutics has a net margin of -289.05% compared to INmune Bio's net margin of -26,333.59%. Cidara Therapeutics' return on equity of -69.64% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune Bio-26,333.59% -117.48% -78.96% Cidara Therapeutics -289.05%-69.64%-33.73% Which has higher earnings and valuation, INMB or CDTX? Cidara Therapeutics has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$42K2,407.25-$30.01M-$2.18-2.09Cidara Therapeutics$63.90M1.67-$22.93M-$25.52-0.59 Do institutionals and insiders hold more shares of INMB or CDTX? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 35.2% of INmune Bio shares are owned by insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend INMB or CDTX? INmune Bio presently has a consensus price target of $20.00, indicating a potential upside of 338.60%. Cidara Therapeutics has a consensus price target of $30.50, indicating a potential upside of 101.72%. Given INmune Bio's higher probable upside, analysts clearly believe INmune Bio is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk and volatility, INMB or CDTX? INmune Bio has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. SummaryCidara Therapeutics beats INmune Bio on 13 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$101.10M$2.94B$5.01B$8.81BDividend YieldN/A1.89%5.21%4.07%P/E Ratio-2.0943.12126.5217.52Price / Sales2,407.25359.351,203.9085.12Price / CashN/A160.0933.3732.51Price / Book2.203.734.684.68Net Income-$30.01M-$41.63M$118.36M$225.62M7 Day Performance-20.28%-7.94%-2.46%-2.04%1 Month Performance-10.76%-7.19%-4.06%0.03%1 Year Performance-39.12%23.01%29.55%24.47% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio2.2804 of 5 stars$4.56-3.2%$20.00+338.6%-39.1%$104.43M$160,000.00-2.0910CDTXCidara Therapeutics4.1784 of 5 stars$15.12-3.3%$30.50+101.7%+0.9%$106.60M$63.90M-0.5990XFORX4 Pharmaceuticals4.0047 of 5 stars$0.34-8.1%$2.88+744.6%-57.4%$58.06MN/A-4.0980Analyst RevisionFBIOFortress Biotech3.046 of 5 stars$1.57-1.3%$13.67+770.5%-43.9%$43.33M$84.51M-0.51186Analyst ForecastAnalyst RevisionAGTCApplied Genetic Technologies0.1172 of 5 stars$0.39flatN/AN/A$26.62M$320,000.00-0.2783MBIOMustang Bio1.9408 of 5 stars$0.21-4.6%$2.00+856.9%-87.6%$10.55MN/A0.00100VERVVerve Therapeutics2.4352 of 5 stars$4.55-6.0%$25.75+465.9%-63.2%$409.77M$11.76M0.00110LRMRLarimar Therapeutics3.678 of 5 stars$6.08-4.7%$20.43+236.0%+93.6%$407.09MN/A0.0030Analyst ForecastCGCCanopy Growth1.469 of 5 stars$3.76-1.8%$3.50-6.9%-36.3%$403.53M$220.27M0.001,029FDMT4D Molecular Therapeutics2.7097 of 5 stars$8.41-3.0%$47.00+458.9%-32.1%$400.79M$20.72M0.00201Analyst RevisionAKBAAkebia Therapeutics4.0169 of 5 stars$1.79-1.6%$5.75+221.2%+75.5%$390.54M$194.62M-7.78167 Related Companies and Tools Related Companies Cidara Therapeutics Competitors X4 Pharmaceuticals Competitors Fortress Biotech Competitors Applied Genetic Technologies Competitors Mustang Bio Competitors Verve Therapeutics Competitors Larimar Therapeutics Competitors Canopy Growth Competitors 4D Molecular Therapeutics Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INMB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INMB Stock Alerts